Reacts with 4-1BB, a 30 kDa glycoprotein expressed on activated T cells. 4-1BB can be detected on Con A or PHA-stimulated peripheral blood T cells (CD4+ and CD8+) and on CEM cells (human T-cell leukemia) following 2 day PMA and ionomycin stimulation, but not on resting T cells. 4-1BB is reported to be a participant in T-cell activation, being responsible for rescuing T cells from activation-induced apoptosis, upregulation of Th1-type, T-helper cells, downregulation of Th2-type cytokine production, and induction of cell adhesion to fibronectin.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
The antibody was conjugated with biotin under optimum conditions, and unreacted biotin was removed.
Storage
4 °C
Storage Comment
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Kim, Broxmeyer: "Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells." in: Journal of hematotherapy & stem cell research, Vol. 10, Issue 4, pp. 441-9, (2001) (PubMed).
Michel, Schwarz: "Expression of soluble CD137 correlates with activation-induced cell death of lymphocytes." in: Cytokine, Vol. 12, Issue 6, pp. 742-6, (2000) (PubMed).
Vinay, Kwon: "Role of 4-1BB in immune responses." in: Seminars in immunology, Vol. 10, Issue 6, pp. 481-9, (1999) (PubMed).
Melero, Shuford, Newby, Aruffo, Ledbetter, Hellström, Mittler, Chen: "Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors." in: Nature medicine, Vol. 3, Issue 6, pp. 682-5, (1997) (PubMed).
Target
CD137 (TNFRSF9)
(Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))